Evaluating the Psychological Burden of Psoriasis and Promise of Mind-Body Interventions
Key Takeaways
- In-depth interviews revealed stigma-driven behaviors and psychosocial impairment as dominant drivers of reduced quality of life, frequently interacting with itch, scaling, pain, fissures, and bleeding.
- Treatment selection reflected preference for oral/injectable modalities but was constrained by perceived trade-offs among efficacy, tolerability, dosing frequency, injection burden, and monitoring requirements.
Psoriasis carries significant psychological and social burden, but adding mind-body approaches like CBT to treatment may improve mental health and outcomes.
Emerging research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting is reinforcing a critical shift in how plaque
Two complementary analyses—one a
Researchers of the first study sought to better understand psoriasis from the patient’s perspective, conducting in-depth interviews with 20 adults across the United States. The findings revealed that the burden of disease extends far beyond physical symptoms, with the researchers noting that these insights can inform the development of a patient-centric value framework for psoriasis, aimed at better aligning treatment decisions with what matters most to patients.1
Participants consistently reported psychological and social challenges as some of the most disruptive aspects of living with psoriasis. Feelings of self-consciousness, anxiety, and the need to cover affected skin were among the most frequently cited concerns. Many patients also described strained personal relationships and social withdrawal driven by embarrassment or fear of judgment.
These emotional impacts were often compounded by physical symptoms such as itching, redness, and scaling—each reported by all participants—as well as pain (70%), cracking (75%), and bleeding (75%). Together, these factors contributed to a cycle of discomfort and distress that affected daily functioning, work performance, and quality of life. Other symptoms, though less common, included tenderness (60%), burning (50%), patches (50%), joint issues (35%), and lesions (35%).
The study also highlighted patient preferences and frustrations with available treatments. While many participants favored oral or injectable therapies over topical options, treatment decisions were heavily influenced by perceived trade-offs. Common concerns included limited effectiveness, side effects, frequent dosing, and the burden of injections or monitoring requirements.
Importantly, when asked about treatment goals, most patients prioritized complete symptom clearance above all else. This was followed by the duration of response and convenience, underscoring a desire for therapies that deliver both effectiveness and sustained benefit.
A second analysis examined the relationship between psychological stress and psoriasis, as well as the potential role of CBT in improving outcomes. Stress is widely recognized as both a trigger and exacerbating factor in psoriasis. Psychological stress can contribute to disease onset, increase flare frequency, and worsen quality of life. Psoriasis is also commonly associated with psychiatric comorbidities, including anxiety and depression.2
CBT, a structured psychological intervention focused on modifying thought patterns and behaviors, has been explored as a potential tool to address these challenges. A review of recent studies suggests that CBT may offer meaningful benefits for patients with psoriasis, particularly in improving mental health outcomes. Together, insights from nearly 200 participants were included, with interventions spanning group CBT, internet CBT, and CBT with biofeedback.
One group-based CBT intervention demonstrated improvements in anxiety, insomnia, depressive symptoms, and social functioning, although it did not significantly change disease severity. Another study of internet-based CBT found improvements in daily functioning and disease-related impact, though effects on emotional distress were more limited.
Notably, a study combining CBT with biofeedback showed broader benefits, including improvements in both skin symptoms and psychological well-being. As summarized in the results section on page 4, this combined approach led to measurable reductions in disease severity alongside enhanced quality of life.
Researchers emphasized that while current evidence is promising, larger and longer-term studies are needed to better understand the full impact of CBT on disease progression and long-term outcomes.
References
1. Caloyeras J, Hyman J, Bacharach M, et al. The development of a US patient-centric value framework in plaque psoriasis: psychological, emotional and social impacts of the disease. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. Poster 73312.
2. Jhingan I, Azzun S, Cline E. Stress, skin, and CBT: evaluating mind–body interventions in psoriasis care. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. Poster 76352.